Current treatment paradigms for triple-negative breast cancer
Related Experiment Video
Updated: Jun 20, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Sumeet K Yadav1, Roberto A Leon-Ferre2
1Department of Hospital Internal Medicine, Mayo Clinic Health System, Mankato, MN, USA - yadav.sumeet@mayo.edu.
Abstract:
Triple negative breast cancer (TNBC) accounts for 15% of all breast cancers and is characterized by more aggressive biology, significant disease heterogeneity, and worse clinical outcomes. In recent years, improved understanding of TNBC tumor biology and its heterogeneity have led to the identification of new molecular targets, opening avenues for novel treatment strategies. Clinical trials evaluating immunotherapy, poly-ADP ribose polymerase (PARP) inhibitors, and antibody drug conjugates have shown improvement in clinical outcomes, leading to their incorporation to the treatment options available for patients with TNBC. This review aimed to provide the internal medicine specialist and primary care provider with a comprehensive overview of the current systemic therapy approaches for TNBC and introduce clinicians to novel therapies that have recently been added to the treatment armamentarium against this disease.
Insights
Triple negative breast cancer (TNBC) is aggressive and diverse. Novel therapies like immunotherapy and PARP inhibitors are improving outcomes for TNBC patients.
Area of Science:
- Oncology
- Medical Research
Background:
- Triple negative breast cancer (TNBC) comprises 15% of all breast cancers.
- TNBC is known for its aggressive nature, heterogeneity, and poorer prognosis.
Purpose of the Study:
- To offer a comprehensive overview of current systemic therapies for TNBC.
- To introduce novel treatments recently incorporated into TNBC management.
Main Methods:
- Review of current scientific literature and clinical trial data.
- Synthesis of information on established and emerging TNBC treatment modalities.
Main Results:
- Advancements in understanding TNBC biology have identified new molecular targets.
- Immunotherapy, PARP inhibitors, and antibody-drug conjugates show improved clinical outcomes.
Conclusions:
- New therapeutic strategies are enhancing treatment options for TNBC.
- Internal medicine specialists and primary care providers need awareness of these evolving treatments.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

